Latest Market Expansion News

Oakridge International Limited reports a strong quarterly performance driven by increased contracted orders, strategic partnerships, and technological innovation, positioning the company for sustained growth into 2025.

DTI Group Limited has inked a global Master Framework Agreement with Siemens Mobility GmbH, streamlining worldwide purchasing and opening doors to new rail and bus sector projects. Despite a modest cash balance, DTI is advancing its flagship software, positioning itself for growth.

RooLife Group Ltd (ASX:RLG) reports a remarkable 144% jump in Q2 FY25 sales revenue, driven by new online stores and strategic market entries into China and India. The company’s own branded health and wellness products are central to its growth strategy.

Inventis Limited reported robust Q2 progress with over $5.7 million in confirmed orders and a $2.5 million capital raise underway in the US, signaling strong momentum in its technology-driven growth strategy.

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.

Nova Eye Medical has completed a $6.6 million placement to fund growth initiatives, supported by strong global sales growth and a major shareholder commitment. The capital raise aims to bolster sales teams and product development as the company targets profitability in its glaucoma division.

Australian Bond Exchange Holdings reports a halving of its operating cash flow shortfall in Q2 FY25, driven by a successful cost reduction program and the launch of a new market-linked security. The company is accelerating its AI initiatives to enhance compliance and transaction efficiency.

BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.

Zimi Limited has secured $2.495 million through a capital raising, appointed new board members, and initiated cost-saving measures exceeding $400,000 annually, while navigating a compliance issue affecting sales to a major distributor.

Mesoblast Limited is set to launch Ryoncil®, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease, backed by a recent $160 million financing that strengthens its commercial and clinical development efforts.

Careteq Limited reports solid progress in integrating its Embedded Health Solutions with HMR Referrals, alongside a 14% revenue increase and improved cash flow in Q2 FY25.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.